• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 12, 2015

View Archived Issues

Pfizer makes $87.5M wager on AM-Pharma's phase II AKI drug

LONDON – Pending positive results from an ongoing phase II trial of its human recombinant alkaline phosphatase in acute kidney injury (AKI), AM-Pharma NV is to be acquired by Pfizer Inc. for $600 million. Read More

Formula One: CAR-CIK to make queasy riders of others in T-cell race?

CEO Maurits Geerlings told BioWorld Today that Formula Pharmaceuticals Inc. may have found a way around the drawbacks of chimeric antigen receptor (CAR) methods that deploy autologous T cells, thanks to the worldwide exclusive license the firm has gained to an allogeneic, nonviral CAR platform that leverages instead cytokine-induced killer (CIK) cells as immune effectors. Read More

NDRC: Reforms aimed at removing price caps, boosting local access

HONG KONG – In a move that could lead to more and easier access to better medicines at the local level, China plans to eliminate fixed prices for drugs next month. And, despite public concerns, the regulator said drug prices will not shoot up even after price caps are taken away. Read More

Binge drinking tied to G protein channel subunit

In animal studies, researchers have tied levels of the G protein-coupled channel subunit, GIRK3, in a midbrain area known as the ventral tegmental area (VTA), to the propensity to binge drink. Read More

Curemark closes in on gut mechanism in autism with second phase III

Privately held Curemark LLC launched an additional phase III trial of its chymotrypsin modulator, CM-AT, that will enroll a broad population of children with autism, ages 3 to 8, after a previous phase III of the compound met the endpoints in the same age group of children with autism who had low levels of chymotrypsin, a digestive enzyme. Read More

Ligand broadens royalty rights portfolio after beating Q1 views

With rising royalty revenue boosting its first quarter earnings, Ligand Pharmaceuticals Inc. added rights to potential future milestone and royalty payments on 15 biologic development programs from its existing partner, Selexis SA, for $4 million in cash. Read More

Financings

Precision Biosciences Inc., of Research Triangle Park, N.C., closed a $25.6 million series A financing led by Venbio. Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners, the Longevity Fund and unnamed investors also participated in the oversubscribed financing. Read More

Other news to note

Isarna Therapeutics GmbH, of Munich, Germany, disclosed preclinical data for its lead candidate, ISTH0036, a locked nucleic acid-modified antisense oligonucleotide, in phase I development for the treatment of advanced-stage glaucoma. Read More

Stock movers

Read More

Appointments and advancements

Zogenix Inc., of San Diego, named Stephen Farr CEO, and he will continue as president. Read More

In the clinic

Heat Biologics Inc., of Durham, N.C., said it launched a phase Ib trial of viagenpumatucel-L (HS-110) in patients with non-small-cell lung cancer, aimed at combining the therapy with multiple immune-modulating strategies. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe